Funding medical researchers to accelerate into practice promising drugs and devices
This MRFF grant funds Australian organisations to partner with small to medium enterprises (SMEs) to accelerate into practice promising drugs and devices focused on cardiovascular disease and the complications of diabetes (types 1 and 2).
Funding supports projects through competitively selected national organisation(s) to promote commercialisation and translation of medical research and innovation.
Eligible organisations seeking to accelerate into practice promising drugs and devices that reduce the burden of cardiovascular disease and complications of diabetes.
The successful independent organisation(s) will be responsible for ensuring that the funding by each organisation:
- targets investment and related support through partnership projects to accelerate promising drug (topic A) or device (topic B) development projects
- promotes commercialisation of novel drugs and devices for cardiovascular disease and for complications of diabetes (types 1 and 2)
- provides a maximum of $1.5 million for each promising drug/device project
- leverages support (including co-funding) from partner organisations such as industry
- provides a minimum investment of $3 million into each of the following: cardiovascular disease
- the disease-related complications in people with type 1 diabetes
- and the disease-related complications in people with type 2 diabetes
Get a personalised eligibility check — your match score, which criteria you meet, and what to watch out for.
Free to search · No credit card required
Last updated: 12 February 2026